Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Symptom-triggered Testing Detects Early Stage And Low Volume Resectable Advanced Stage Ovarian Cancer

Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer

Fong Lien Audrey Kwong1,2, Caroline Kristunas2, Clare Davenport2

  • 1The Pan-Birmingham Gynaecological Cancer Centre, Sandwell and West Birmingham NHS Trust, Birmingham, UK.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|August 13, 2024

Related Experiment Videos

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
10:21

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions

Published on: March 3, 2023

1.4K
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.1K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K

View abstract on PubMed

Summary
This summary is machine-generated.

Symptom-triggered testing identified early-stage high grade serous ovarian cancer in one in four women. This fast-track pathway may improve detection of low disease burden, potentially increasing complete cytoreduction rates.

Area of Science:

  • Gynecologic Oncology
  • Diagnostic Test Accuracy
  • Ovarian Cancer Research

Background:

  • Symptom-triggered testing for ovarian cancer involves ultrasound and CA125 testing, with rapid referral for abnormal results.
  • The effectiveness of this pathway in detecting early-stage high grade serous ovarian cancer (HGSOC) or low tumor burden is not well-established.

Purpose of the Study:

  • To describe the International Federation of Gynecology and Obstetrics (FIGO) stage, disease distribution, and complete cytoreduction rates in women with HGSOC diagnosed via the UK's fast-track pathway.
  • To evaluate the potential of symptom-triggered testing in identifying early-stage disease or low tumor burden.

Main Methods:

  • Analysis of data from the prospective diagnostic accuracy study ROCkeTS (Refining Ovarian Cancer Test accuracy Scores).
  • Inclusion of women diagnosed with HGSOC via the fast-track pathway between June 2015 and July 2022.
Keywords:
Cystadenocarcinoma, SerousCytoreduction surgical proceduresOvarian CancerSurgical Oncology

Related Experiment Videos

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
10:21

A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions

Published on: March 3, 2023

1.4K
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.1K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K
  • Reporting on demographics, performance status, FIGO stage, disease distribution, and cytoreduction rates in women who underwent surgery.

    • Main Results:

    • Of 1741 participants, 119 (6.8%) had HGSOC. Median age was 63 years.
    • 25.2% were diagnosed with FIGO stages I/II, with low-to-moderate disease distribution in 64.7%.
    • Complete cytoreduction was achieved in 61.3% of patients; 65.5% underwent primary debulking surgery.

    Conclusions:

    • Symptom-triggered testing via the fast-track pathway identified early-stage HGSOC in approximately one in four women.
    • This pathway shows potential for detecting women with low disease burden, possibly leading to higher rates of complete cytoreduction.